August 2, 2010Current Medical Research and Opinion
Treatment patterns in patients with acute coronary syndrome undergoing percutaneous coronary intervention
Key result
In a real-world registry of ACS patients undergoing PCI, the composite of CV death, MI, or stroke occurred in 4.7% of patients at 12 months, with marked variation in management across countries.
Why the study?
What are the real-world treatment patterns and 12-month clinical outcomes in ACS patients undergoing PCI in Europe?
Study Design
Type
Observational (n=1,525)
Multicenter
Yes
Structured PICO
What are the real-world treatment patterns and 12-month clinical outcomes in ACS patients undergoing PCI in Europe?
P
Population
1,525 patients with acute coronary syndrome undergoing percutaneous coronary intervention across three European countries, followed for 12 months.
E
Exposure
Real-world clinical management including antiplatelet therapy (aspirin, clopidogrel) and stent use
O
Outcome
Treatment patterns and composite endpoint of cardiovascular death, myocardial infarction, or stroke at 12 monthscomposite
This registry highlights significant regional variations in antiplatelet dosing and stent selection for ACS patients undergoing PCI across Europe, with a 4.7% 1-year rate of major adverse cardiovascular events.
Limitations
- Observational design of the registry
- Statistical testing was not applied and data should be seen as hypothesis generating
- Observational design
- Statistical testing was not applied (hypothesis generating only)
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
European ACS PCI management varies widely; leaves open whether standardization improves outcomes.
Cite This Study
Ferrières et al. (2010) conducted an observational in acute coronary syndrome (n=1,525). Real-world management (antiplatelet therapy, co-medications, and stents) was evaluated on composite endpoint of cardiovascular (CV) death, MI or stroke. In a real-world registry of ACS patients undergoing PCI, the composite of CV death, MI, or stroke occurred in 4.7% of patients at 12 months, with marked variation in management across countries.